Regional Growth Fund Success Sees Malvern Instruments Stepping up UK Recruitment
News May 20, 2014
Malvern Instruments has been successful in securing £3 million support from the UK Government’s Regional Growth Fund (RGF) that will lead to the creation of 47 new jobs in the UK over the next five years.
Malvern develops, manufactures and markets materials and biophysical characterization systems. These are used to measure particle size, particle shape, zeta potential, protein charge, molecular weight, mass, size and conformation, rheology and for chemical identification.
This funding will support the research and development of new analytical instrumentation to serve the fast-growing nanomaterials and bioscience sectors, helping maximize Malvern’s export opportunities in these global markets. The company, which currently employs around 340 people in the UK and approaching 480 more in locations around the world, has already started recruiting to fill a variety of new posts.
“This major boost for Malvern Instruments enables us make significant investments in UK R&D, applications development and manufacturing engineering, to extend our links with UK universities and schools and to invest further in our apprentice programme,” said Managing Director Paul Walker. “It is good news not just for the company but also for the wider community in creating and securing employment opportunities and contributing further to the local economy.”
Malvern’s systems are used in research, development and manufacturing across many different industries. They provide information that is critical for developing new products, as well as for enhancing and maintaining product quality and improving process efficiency.
“The Bioscience and Nanomaterials markets require novel analytical techniques and the RGF funding will support our fundamental research in these areas, as well as enabling us to further develop the skills of new and existing employees,” continued Paul Walker. “Not only will we be looking to recruit additional R&D scientists, we are also creating new jobs in manufacturing engineering and operations to enable us to bring new products to market.”
Comments | 0 ADD COMMENT
U.S. FDA Accepts Licence For Biosimilar Trastuzumab
News Jan 12, 2017